Short answer
Immunome Inc. (IMNM) filed an 8-K current report with the SEC on March 3, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Full-year 2025 financial results released March 3, 2026: complete figures in Exhibit 99.1.
Immunome Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Full-year 2025 financial results released March 3, 2026: complete figures in Exhibit 99.1
- IMNM is a clinical-stage biotech; results likely reflect R&D burn rate and cash runway, key metrics for investors
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Immunome Inc. 8-K filings
Get the next IMNM 8-K as it lands
Follow IMNM for push alerts, or ask the research agent what this filing means.